ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,217.60
      0.28%
      Dow Jones
      39,118.86
      0.00%
      Brent Oil
      85.545
      0.51%
      Bitcoin
      62,641.39
      0.07%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Galectin Therapeutics Inc (GALT)

      7. Galectin Therapeutics Inc (GALT) News

      GALT

      Galectin Therapeutics (GALT)

      Galectin Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GALT
      DateTimeSourceHeadlineSymbolCompany
      05/09/20239:43AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      04/27/20238:00AMGlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023NASDAQ:GALTGalectin Therapeutics Inc
      04/25/20236:06AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:GALTGalectin Therapeutics Inc
      04/18/20238:00AMGlobeNewswire Inc.Galectin Therapeutics’ Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver DiseasesNASDAQ:GALTGalectin Therapeutics Inc
      04/17/20238:00AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      04/14/20235:27PMEdgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:GALTGalectin Therapeutics Inc
      04/03/20238:30AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      03/30/20234:01PMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:GALTGalectin Therapeutics Inc
      03/30/20238:00AMGlobeNewswire Inc.Galectin Therapeutics Reports 2022 Financial Results and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
      03/30/20237:54AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      03/16/202311:35AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      03/16/20238:00AMGlobeNewswire Inc.Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisNASDAQ:GALTGalectin Therapeutics Inc
      03/02/20238:00AMGlobeNewswire Inc.Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisNASDAQ:GALTGalectin Therapeutics Inc
      03/02/20237:56AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      03/02/20237:49AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      02/21/202312:17PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      02/21/20238:31AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      02/15/20234:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      02/07/20237:44AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/31/20234:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/30/20234:56PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/30/20234:49PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/30/20234:47PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/30/20234:41PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/30/20234:40PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/30/20234:35PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/26/20237:45AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/24/20238:00AMGlobeNewswire Inc.Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology JournalNASDAQ:GALTGalectin Therapeutics Inc
      01/17/20237:51AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      01/05/20238:00AMGlobeNewswire Inc.Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisNASDAQ:GALTGalectin Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:GALT